top of page

Ciclosporin

Grade

Keratoconjunctivitis Sicca (KCS)

Administration Advice

  • [AWAITING DATA]

Therapeutics

Therapeutic Considerations

  1. Administration Advice: [AWAITING DATA]

  2. Multimodal Use: When treating [AWAITING DATA] in [AWAITING DATA], [AWAITING DATA] is often administered alongside [AWAITING DATA].

  3. Adverse Effects Profile: These are [AWAITING DATA] at therapeutic dosage. The most commonly encountered adverse effects are m[AWAITING DATA]. [AWAITING DATA] are also possible.

  4. Reproductive Safety: [AWAITING DATA] in breeding animals and during pregnancy and lactation. See the information referenced within the [AWAITING DATA] monograph for additional detail.

  5. Treatment Goals: The usual treatment goal is to reduce the severity and duration of neuropathic pain. Little verified information is available regarding monitoring [AWAITING DATA], which means the treatment goal is a subjective observation.

  6. Treatment Endpoints: Setting treatment endpoints (circumstances where medication is withdrawn) requires suitable patient monitoring on a case-by-case basis. Typical treatment endpoints are [AWAITING DATA].

  7. Efficacy Profile: [AWAITING DATA]

  8. Alternative Products: [AWAITING DATA]

  9. Alternative Protocols: [AWAITING DATA]

  10. Clinical Review: [AWAITING DATA]

Evidence

Monograph Details

bottom of page